Tags : CT-P42


Celltrion Initiates P-III Study of CT-P42 (biosimilar, aflibercept)

Shots: Celltrion has launched a global P-III clinical trial of CT-P42 which is an investigational biosimilar candidate referencing Regeneron’s Eylea (aflibercept) The study will enroll 300 patients with DME and aims to compare CT-P42’s efficacy, safety, pharmacokinetics, and immunogenicity against Eylea Celltrion adds CT-P42 to its pipeline of other investigational biosimilars, including CT-P17 (referencing Humira), […]Read More